Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEHOLD-Ovarian01: Mocertatug rezetecan vs standard of care in platinum-resistant ovarian cancer
jRCT2011260018Phase 3Recruiting
- Sponsor
- GSK
- Start
- Jul 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial in ovarian cancer comparing Mocertatug rezetecan with Physician's choice standard of care (2 arms). Primary endpoints: Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) and Overall Survival (OS). Started Jul 2026; status: recruiting.
02
Drugs
mocertatug rezetecan
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on jRCT2011260018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011260018.